State of Alaska Department of Revenue Has $458,000 Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

State of Alaska Department of Revenue decreased its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 9.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,397 shares of the medical equipment provider’s stock after selling 735 shares during the quarter. State of Alaska Department of Revenue’s holdings in Lantheus were worth $458,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Fairfield Bush & CO. acquired a new stake in shares of Lantheus during the first quarter valued at about $177,000. Raymond James & Associates acquired a new stake in Lantheus during the 1st quarter worth approximately $856,000. Bank of New York Mellon Corp grew its holdings in Lantheus by 2.7% during the 1st quarter. Bank of New York Mellon Corp now owns 629,033 shares of the medical equipment provider’s stock worth $34,791,000 after acquiring an additional 16,422 shares during the last quarter. American Century Companies Inc. increased its position in Lantheus by 14.4% in the 1st quarter. American Century Companies Inc. now owns 19,235 shares of the medical equipment provider’s stock valued at $1,064,000 after acquiring an additional 2,427 shares during the period. Finally, HighTower Advisors LLC bought a new position in shares of Lantheus during the first quarter valued at $354,000. Institutional investors own 99.06% of the company’s stock.

Insider Activity

In other news, Director Mary Anne Heino sold 93,863 shares of the firm’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $65.31, for a total value of $6,130,192.53. Following the completion of the sale, the director now directly owns 251,643 shares in the company, valued at approximately $16,434,804.33. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In related news, Director Mary Anne Heino sold 93,863 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $65.31, for a total value of $6,130,192.53. Following the transaction, the director now directly owns 251,643 shares in the company, valued at approximately $16,434,804.33. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of Lantheus stock in a transaction that occurred on Wednesday, March 6th. The stock was acquired at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the transaction, the insider now owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 94,545 shares of company stock worth $6,168,153. Company insiders own 1.50% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on LNTH shares. Truist Financial reissued a “buy” rating and issued a $82.00 price objective (up previously from $80.00) on shares of Lantheus in a research note on Monday, February 26th. StockNews.com raised Lantheus from a “hold” rating to a “buy” rating in a research note on Saturday, January 13th. TheStreet downgraded Lantheus from a “b-” rating to a “c” rating in a research report on Monday, December 18th. William Blair cut Lantheus from an “outperform” rating to a “market perform” rating in a report on Monday, December 18th. Finally, B. Riley lowered their price target on shares of Lantheus from $113.00 to $95.00 and set a “buy” rating for the company in a report on Wednesday, January 10th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $104.14.

Lantheus Trading Down 1.2 %

Shares of LNTH stock opened at $60.79 on Friday. The company has a market cap of $4.17 billion, a P/E ratio of 13.10 and a beta of 0.53. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $100.85. The stock has a 50 day simple moving average of $60.13 and a two-hundred day simple moving average of $63.16. The company has a debt-to-equity ratio of 0.69, a quick ratio of 5.45 and a current ratio of 5.80.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share for the quarter, beating the consensus estimate of $1.33 by $0.26. The company had revenue of $354.00 million during the quarter, compared to analyst estimates of $350.44 million. Lantheus had a net margin of 25.20% and a return on equity of 63.16%. Research analysts forecast that Lantheus Holdings, Inc. will post 5.72 earnings per share for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.